For the anti-interleukin-6 receptor antibody tocilizumab, approved for DMARD-refractory polyarticular JIA and systemic JIA [11], the ACR Pedi 30 response rate was 95 % at week 12 and 100 % at week 48 [24]. Here, IL6R is linked to polyarticular juvenile idiopathic arthritis.